Stuart Kupfer

8.9k total citations · 4 hit papers
82 papers, 5.6k citations indexed

About

Stuart Kupfer is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics. According to data from OpenAlex, Stuart Kupfer has authored 82 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Cardiology and Cardiovascular Medicine, 44 papers in Endocrinology, Diabetes and Metabolism and 13 papers in Nutrition and Dietetics. Recurrent topics in Stuart Kupfer's work include Blood Pressure and Hypertension Studies (28 papers), Hormonal Regulation and Hypertension (24 papers) and Diabetes Treatment and Management (20 papers). Stuart Kupfer is often cited by papers focused on Blood Pressure and Hypertension Studies (28 papers), Hormonal Regulation and Hypertension (24 papers) and Diabetes Treatment and Management (20 papers). Stuart Kupfer collaborates with scholars based in United States, United Kingdom and Italy. Stuart Kupfer's co-authors include George L. Bakris, William B. White, William C. Cushman, Faı̈ez Zannad, Christopher P. Cannon, Cyrus R. Mehta, Alfonso T. Perez, Craig Wilson, P. Fleck and Steven E. Nissen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Stuart Kupfer

71 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

2013 1.9k citations William B. White, Christopher P. Cannon et al. profile →
Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

2008 664 citations Steven E. Nissen, Stephen J. Nicholls et al. JAMA profile →
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

2015 551 citations Faı̈ez Zannad, Christopher P. Cannon et al. profile →
Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?

2006 507 citations Giuseppe Mancia, Ann C. Hewkin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart Kupfer United States	27	4.0k	2.3k	1.6k	1.3k	505	82	5.6k
Yan Gong United States	39	1.4k 0.4×	1.8k 0.8×	1.3k 0.8×	695 0.5×	593 1.2×	200	4.9k
Frederik Persson Denmark	40	3.3k 0.8×	2.4k 1.0×	1.2k 0.7×	991 0.8×	135 0.3×	182	6.3k
Jennifer B. Green United States	31	3.6k 0.9×	1.5k 0.6×	1.4k 0.8×	1.3k 1.0×	474 0.9×	91	5.0k
Stuart Warren United States	15	3.3k 0.8×	1.4k 0.6×	944 0.6×	812 0.6×	146 0.3×	22	5.6k
Lars Rydén Sweden	41	3.9k 1.0×	3.2k 1.4×	1.3k 0.8×	981 0.8×	119 0.2×	161	6.7k
Michael G. Silverman United States	22	4.5k 1.1×	2.0k 0.9×	1.9k 1.1×	2.6k 2.0×	116 0.2×	44	6.8k
Michael Szarek United States	34	3.3k 0.8×	2.4k 1.0×	1.0k 0.6×	3.9k 3.0×	352 0.7×	127	7.4k
Matthew A. Cavender United States	28	4.7k 1.2×	2.3k 1.0×	2.0k 1.2×	2.1k 1.6×	684 1.4×	86	6.7k
Jaime A. Davidson United States	35	6.6k 1.7×	1.1k 0.5×	2.4k 1.5×	2.7k 2.0×	784 1.6×	98	8.2k
Michael C dʼEmden Australia	22	2.9k 0.7×	1.1k 0.5×	1.0k 0.6×	2.4k 1.8×	159 0.3×	72	5.4k

Countries citing papers authored by Stuart Kupfer

Since Specialization

Citations

This map shows the geographic impact of Stuart Kupfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Kupfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Kupfer more than expected).

Fields of papers citing papers by Stuart Kupfer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Kupfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Kupfer. The network helps show where Stuart Kupfer may publish in the future.

Co-authorship network of co-authors of Stuart Kupfer

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Kupfer. A scholar is included among the top collaborators of Stuart Kupfer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Kupfer. Stuart Kupfer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kaski, Juan Pablo, Paul F. Kantor, Stephanie J. Nakano, et al.. (2025). Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Circulation Heart Failure. 19(2). e013418–e013418.

Rudnicki, Stacy A., Stuart Kupfer, Fady I. Malik, et al.. (2025). Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 26(7-8). 812–820.

Chimura, Misato, Kieran F. Docherty, Pardeep S. Jhund, et al.. (2025). Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. European Heart Journal. 47(1). 69–79.

Simkins, Tyrell, Jianlin Li, Priyanka Solanki, et al.. (2025). EVALUATION OF CYTOCHROME P450 2C9, 2C19, AND 2D6 INHIBITION ON THE PHARMACOKINETICS OF AFICAMTEN IN HEALTHY PARTICIPANTS. Journal of the American College of Cardiology. 85(12). 1428–1428.

Coats, Caroline, Theodore P. Abraham, Michael E. Nassif, et al.. (2025). Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials. Heart Rhythm. 23(1). 212–214.

Adamo, Marianna, Marco Metra, Brian Claggett, et al.. (2024). Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure. 12(3). 552–563. 10 indexed citations

Shefner, Jeremy M., Stuart Kupfer, Fady I. Malik, et al.. (2023). Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 25(1-2). 162–169.

Docherty, Kieran F., Brian Claggett, Rafael Díaz, et al.. (2022). THE EFFECT OF OMECAMTIV MECARBIL IN HOSPITALIZED PATIENTS AS COMPARED WITH OUTPATIENTS: A PRESPECIFIED ANALYSIS OF GALACTIC-HF. Journal of the American College of Cardiology. 79(9). 310–310. 1 indexed citations

Shimada, Yuichi J., Christopher P. Cannon, Yuyin Liu, et al.. (2016). Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. American Heart Journal. 175. 18–27. 5 indexed citations

10.

White, William B., et al.. (2016). Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. Journal of Hypertension. 34(4). 788–797. 26 indexed citations

11.

Vaduganathan, Muthiah, Javed Butler, Lothar Roessig, et al.. (2015). Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. Heart Failure Reviews. 20(4). 393–400. 3 indexed citations

12.

Bates, Eric R., Deepak L. Bhatt, David R. Holmes, et al.. (2014). Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thrombosis and Haemostasis. 111(6). 1141–1152. 25 indexed citations

13.

Gheorghiade, Mihai, Ami N. Shah, Muthiah Vaduganathan, et al.. (2013). Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Heart Failure Clinics. 9(3). 285–290. 28 indexed citations

14.

Bakris, George L., Domenic Sica, William B. White, et al.. (2012). Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. The American Journal of Medicine. 125(12). 1229.e1–1229.e10. 74 indexed citations

15.

Nicholls, Stephen J., E. Murat Tuzcu, Kathy Wolski, et al.. (2011). Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. Journal of the American College of Cardiology. 57(2). 153–159. 82 indexed citations

16.

Nicholls, Stephen J., Özgür Bayturan, Tao Hu, et al.. (2008). Abstract 5052: Lowering of the Triglyceride/HDL Cholesterol Ratio Predicts the Benefit of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients. Circulation. 118(4). 305–307. 3 indexed citations

17.

Nissen, Steven E., Stephen J. Nicholls, Kathy Wolski, et al.. (2008). Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes. JAMA. 299(13). 1561–1561. 664 indexed citations breakdown →

18.

Wilcox, Robert, Stuart Kupfer, & Erland Erdmann. (2008). Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). American Heart Journal. 155(4). 712–717. 101 indexed citations

19.

Pepine, Carl J., Peter R. Kowey, Stuart Kupfer, et al.. (2006). Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease. Journal of the American College of Cardiology. 47(3). 547–551. 39 indexed citations

20.

Mancia, Giuseppe, Mátyás Keltai, Serap Erdine, et al.. (2004). Risk of adverse cardiovascular outcomes and new diabetes with combination therapy in hypertensive patients with coronary artery disease: the INternational VErapamil SR-Trandolapril STudy (INVEST). European Heart Journal. 25. 423–424.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact